These medications include semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) for both diabetes and weight management, and liraglutide (Victoza for diabetes, Saxenda for weight management)
At a glance Drug class / triple agonist: GLP-1, GIP, and glucagon receptor agonist (investigational) Known direct interaction with B12 / none identified to date Indirect depletion risk / present when retatrutide is co-prescribed with metformin Metformin B12 depletion incidence / up to 30% of long-term metformin users show subnormal B12 levels Recommended baseline test / serum B12 (ideally holotranscobalamin) before starting Retest interval / every 12 months on metformin
When tesamorelin binds to GHRH receptors on pituitary somatotroph cells, it triggers the adenylate cyclase-cAMP signaling cascade, which stimulates the synthesis and secretion of endogenous growth hormone in pulsatile bursts that mirror the body natural rhythm
Instead of targeting a single receptor, retatrutide activates three hormone receptors involved in appetite and metabolism: GLP-1 receptor GIP receptor Glucagon receptor Because it activates all three pathways, it is often called a triple agonist
Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, et al
Importantly, this trial compared orforgliprin with oral semaglutide doses that were based on those that are currently available for Rybelsus, but the maximum effective dose offered for the recently approved Wegovy pill for obesity is 25 mg
